These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 15623646

  • 81. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA.
    Cancer Res; 2008 Oct 01; 68(19):8049-57. PubMed ID: 18829563
    [Abstract] [Full Text] [Related]

  • 82. Immunophenotypic variability of B-cell non-Hodgkin lymphoma: a retrospective study of cases analyzed by flow cytometry.
    Echeverri C, Fisher S, King D, Craig FE.
    Am J Clin Pathol; 2002 Apr 01; 117(4):615-20. PubMed ID: 11939737
    [Abstract] [Full Text] [Related]

  • 83. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.
    J Immunother; 2007 Jan 01; 30(1):64-74. PubMed ID: 17198084
    [Abstract] [Full Text] [Related]

  • 84. Antitumor activity of idarubicin-monoclonal antibody conjugates in a disseminated thymic lymphoma model.
    Smyth MJ, Bogdanovski M, McKenzie IF, Pietersz GA.
    Cancer Res; 1991 Jan 01; 51(1):310-7. PubMed ID: 1988093
    [Abstract] [Full Text] [Related]

  • 85. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.
    Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM.
    Blood; 2001 Jan 15; 97(2):528-35. PubMed ID: 11154233
    [Abstract] [Full Text] [Related]

  • 86. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
    Song W, Levy R.
    Cancer Res; 2005 Jul 01; 65(13):5958-64. PubMed ID: 15994975
    [Abstract] [Full Text] [Related]

  • 87. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice.
    Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES.
    Int J Cancer; 1990 Mar 15; 45(3):481-5. PubMed ID: 2307538
    [Abstract] [Full Text] [Related]

  • 88. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
    Buser A, Stern M, Arber C, Medinger M, Halter J, Rovo A, Favre G, Lohri A, Tichelli A, Gratwohl A.
    Bone Marrow Transplant; 2008 Oct 15; 42(7):483-7. PubMed ID: 18695668
    [Abstract] [Full Text] [Related]

  • 89. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
    Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, Coleman M, Leonard JP.
    Semin Hematol; 2008 Apr 15; 45(2):126-32. PubMed ID: 18381108
    [Abstract] [Full Text] [Related]

  • 90. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.
    de Vries JF, Zwaan CM, De Bie M, Voerman JS, den Boer ML, van Dongen JJ, van der Velden VH.
    Leukemia; 2012 Feb 15; 26(2):255-64. PubMed ID: 21869836
    [Abstract] [Full Text] [Related]

  • 91. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.
    Kato J, Satake N, O'Donnell RT, Abuhay M, Lewis C, Tuscano JM.
    Leuk Res; 2013 Jan 15; 37(1):83-8. PubMed ID: 23040543
    [Abstract] [Full Text] [Related]

  • 92. Inotuzumab ozogamicin as novel therapy in lymphomas.
    Wong BY, Dang NH.
    Expert Opin Biol Ther; 2010 Aug 15; 10(8):1251-8. PubMed ID: 20528256
    [Abstract] [Full Text] [Related]

  • 93. The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice.
    Wei BR, Ghetie MA, Vitetta ES.
    Clin Cancer Res; 2000 Feb 15; 6(2):631-42. PubMed ID: 10690549
    [Abstract] [Full Text] [Related]

  • 94. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor.
    Kemp JD, Cardillo T, Stewart BC, Kehrberg E, Weiner G, Hedlund B, Naumann PW.
    Cancer Res; 1995 Sep 01; 55(17):3817-24. PubMed ID: 7641199
    [Abstract] [Full Text] [Related]

  • 95. Effect of sublethal irradiation of SCID mice on growth of B-cell lymphoma xenografts and on efficacy of chemotherapy and/or immunotoxin therapy.
    Ghetie MA, Gordon BE, Podar EM, Vitetta ES.
    Lab Anim Sci; 1996 Jun 01; 46(3):305-9. PubMed ID: 8799937
    [Abstract] [Full Text] [Related]

  • 96. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters.
    Govindan SV, Goldenberg DM, Elsamra SE, Griffiths GL, Ong GL, Brechbiel MW, Burton J, Sgouros G, Mattes MJ.
    J Nucl Med; 2000 Dec 01; 41(12):2089-97. PubMed ID: 11138697
    [Abstract] [Full Text] [Related]

  • 97. Single tumor cell uptake and dosimetry of technetium-99m Fab' or minute anti-CD22 in low-grade B-cell lymphoma.
    Lindén O, Hindorf C, Tennvall J, Segrén S, Wingardh K, Strand SE.
    Cancer; 2002 Feb 15; 94(4 Suppl):1270-4. PubMed ID: 11877756
    [Abstract] [Full Text] [Related]

  • 98. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics.
    Hursey M, Newton DL, Hansen HJ, Ruby D, Goldenberg DM, Rybak SM.
    Leuk Lymphoma; 2002 May 15; 43(5):953-9. PubMed ID: 12148905
    [Abstract] [Full Text] [Related]

  • 99. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
    Waurzyniak B, Schneider EA, Tumer N, Yanishevski Y, Gunther R, Chelstrom LM, Wendorf H, Myers DE, Irvin JD, Messinger Y, Ek O, Zeren T, Langlie MC, Evans WE, Uckun FM.
    Clin Cancer Res; 1997 Jun 15; 3(6):881-90. PubMed ID: 9815763
    [Abstract] [Full Text] [Related]

  • 100. The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma.
    Cheadle EJ, Gilham DE, Hawkins RE.
    Br J Haematol; 2008 Jul 15; 142(1):65-8. PubMed ID: 18477047
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.